Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Leukemia 10Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid, Acute 7Blast Crisis 7Neoplasms 6Leukemia, Myeloid, Accelerated Phase 6Myeloproliferative Disorders 5Carcinoma, Non-Small-Cell Lung 5Neoplasms by Histologic Type 4Leukemia, Myeloid 4Hematologic Diseases 4Bone Marrow Diseases 4Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thrombocytosis 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1

Interventions

ibrutinib 9tofacitinib 7Imatinib Mesylate 5ruxolitinib 4ofatumumab 4Rituximab 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Sirolimus 3Mycophenolic Acid 3Cyclophosphamide 3obinutuzumab 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Filgrastim 2Alemtuzumab 2ziconotide 1sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1milatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bronchiolitis Obliterans Syndrome × ponatinib × Clear all
NCT04043676 2019-08-02

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Fundación Teófilo Hernando, Spain

Phase 2 Unknown
40 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚔